HC Wainwright Rates Omeros (OMER) buy, $33 Price Target
HC Wainwright maintains its buy rating on Omeros with a $33 price target, a 233% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Omeros Corporation ($OMER) "buy" with a $33 price target on June 26, 2026.
Since the rating, $OMER is up 19.3% after 1 week, up 30.8% after 1 month and up 86.8% to date (from the $8.67 close on Jun 26, 2026).
OMER
Omeros Corporation
Key Points
- On June 26, 2026, HC Wainwright reiterated its buy rating for Omeros Corporation (OMER) with a price target of $33.
- HC Wainwright's $33 price target implies 233% upside from Omeros Corporation's ($OMER) current $9.91 share price.
- Shares of Omeros traded at $10.72 on Friday, with a market cap of approximately $775.9 million and a P/E ratio of 9.4.
- BlackRock, Inc. increased its Omeros holdings by 247,188 shares, totaling 5,309,626 shares valued at about $56.1 million.
Get $OMER trade alerts by text
We text you when insiders, Congress or big funds trade $OMER. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Omeros Corporation alert may contain errors. Disclosures
HC Wainwright & Co. has reaffirmed its buy rating for Omeros Corporation (NasdaqGM: OMER) as of June 26, 2026. The firm set a price target of $33, indicating confidence in the company's potential upside. Shares of Omeros were trading at $10.72 on Friday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Omeros Corporation Stock Down 46.2%
Shares of NasdaqGM:OMER traded near $10.72 on Friday. Omeros Corporation, with a market cap of approximately $775.9 million, has a price-to-earnings ratio of 9.4. The company's stock has experienced a 52-week low of $2.95 and a high of $17.65. Its 50-day moving average is $12.13, while the 200-day moving average stands at $10.23. Omeros also maintains a current ratio of 3.03 and a quick ratio of 2.48, reflecting its solid liquidity position.
$OMER price target
Omeros Corporation daily closes and this analyst's $33 target. Not advice.
Other Institutional Activity in Omeros Corporation
BlackRock, Inc. increased its holdings in Omeros by 247,188 shares, ending with a total of 5,309,626 shares valued at about $56.1 million, marking a 4.9% increase. Ingalls & Snyder LLC also boosted its position by 110,724 shares, bringing its total to 3,559,423 shares worth roughly $37.6 million, a 3.2% increase. Vanguard Capital Management LLC opened a new position in Omeros with 2,983,259 shares valued at approximately $31.5 million. UBS Group AG added 117,749 shares, resulting in a 5.3% increase, with a total of 2,340,731 shares worth about $24.7 million. State Street Corp grew its stake by 346,049 shares, a 22% increase, reaching 1,919,575 shares valued at $20.3 million.
Insider Buying and Selling at Omeros Corporation
Several insiders made significant stock purchases on June 18, 2026. Leroy Hood, MD, PhD, Diana Perkinson, Rajiv Shah, Thomas Bumol, Arnold Hanish, and Peter Demopulos, MD each acquired 15,000 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On June 26, 2026, HC Wainwright & Co. maintained its buy rating on Omeros Corporation with a price target of $33. The consensus among analysts is a buy rating, with a mean price target of $40 based on the opinions of one analyst.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company based in Seattle, Washington. It focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases. The company is led by CEO Dr. Gregory A. Demopulos and employs around 175 people. Omeros is working on several clinical-stage products, including Narsoplimab for stem-cell transplant-associated thrombotic microangiopathy and other conditions, as well as other therapeutics for various disorders.
Bottom Line
HC Wainwright's reaffirmation of a buy rating with a $33 target price highlights confidence in Omeros Corporation's growth potential. Investors often track analyst ratings for insights into a stock's future performance. It's important to note that these ratings reflect the analysts' views at the time and may not represent current market conditions.
Related Filing Alerts
Source: HC Wainwright's rating change on $OMER (Jun 26, 2026). Written by software, not financial advice. How we make alerts